m+Medelevator.RU
← Поиск публикаций
Molecular pharmaceutics · 2024

Bactericidal Metal-Organic Gallium Frameworks - Synthesis to Application.

СтатьяОбзорПоддержка правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Cordeiro Gomes Fellype Diorgennes, Ferreira Alves Mary Cristina, Alves Júnior Severino, Medina Scott H

Аннотация

Gallium, a trace metal not found in its elemental form in nature, has garnered significant interest as a biocide, given its ability to interfere with iron metabolism in bacteria. Consequently, several gallium compounds have been developed and studied for their antimicrobial properties but face challenges of poor solubility and formulation for delivery. Organizing the metal into three-dimensional, hybrid scaffolds, termed metal-organic frameworks (MOFs), is an emerging platform with potential to address many of these limitations. Gallium MOFs show improved solubility and antibacterial potency relative to the free metal due to their ability to coload antibiotics and functional biomolecules. Synthetic strategies are equally versatile, with several rapid, cost-effective, and scalable methods available. In this review, we present the advantages and disadvantages of these various synthetic strategies with respect to their antibacterial efficiency, product purity, and reaction control. The activity of gallium-based MOFs against Gram-positive and Gram-negative pathogens in mono- and combinatorial therapeutic settings is discussed in the context of their mechanisms of action and structure-function-performance relationships collated from recent studies. While gallium MOF development as antibacterials is still in its nascent stages, the examples discussed here highlight their potential as a novel class of therapeutics poised to impact the fight against pan-drug-resistant bacterial pathogens.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты